Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Description

The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.

Conditions

Basal Cell Carcinoma

Study Overview

Study Details

Study overview

The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.

Alteration of the Immune Microenvironment in Basal Cell Carcinoma (BCC) Following Photodynamic Therapy (PDT)

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Condition
Basal Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic
  • * Must have at least one BCC tumor eligible for removal by surgical excision
  • * Men and women of any ethnic group are eligible
  • * Must provide informed consent to participate
  • * Pregnant or breastfeeding
  • * Currently being treated for other cancers with medical or radiation therapy
  • * Known hypersensitivity to 5-aminolevulinic acid (ALA)
  • * History of a photosensitivity disease, e.g.,porphyria cutanea tarda

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Case Comprehensive Cancer Center,

Edward V Maytin, MD, PhD, PRINCIPAL_INVESTIGATOR, Cleveland Clinic, Case Comprehensive Cancer Center

Study Record Dates

2027-12